Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21791392 | 0.86 | GPR119 (0.45) | GPR119KCNH2CYP3A4KDM4ENPC1 | |
| SCHEMBL27086563 | 0.84 | GPR119 (0.47) | GPR119KCNH2CYP3A4KDM4ENPC1 | |
| SCHEMBL14314910 | 0.82 | GPR119 (0.58) | GPR119KCNH2CYP3A4 | |
| SCHEMBL14247009 | 0.81 | GPR119 (0.46) | GPR119KCNH2KDM4ENPC1RAB9A | |
| SCHEMBL17127012 | 0.81 | GPR119 (0.57) | GPR119KCNH2CYP3A4 | |
| SCHEMBL27086530 | 0.81 | GPR119 (0.43) | GPR119KCNH2CYP3A4AOC3 | |
| SCHEMBL17104651 | 0.80 | GPR119 (0.58) | GPR119KCNH2CYP3A4 | |
| SCHEMBL14967789 | 0.80 | GPR119 (0.58) | GPR119KCNH2CYP3A4 | |
| SCHEMBL15203232 | 0.80 | GPR119 (0.58) | GPR119KCNH2CYP3A4 | |
| SCHEMBL24921761 | 0.80 | HDAC3 (0.46) | GPR119KDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153719-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153719-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | GPR119 1/4885KCNH2 4507/4885CYP3A4 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.